Medtronic annual return on equity
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Medtronic Return on Equity (ROE) Growth & History (MDT)
Medtronic's return on equity was 9.85% for fiscal 2026.
View full Medtronic company overviewMedtronic annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-04-24 | 9.85% | +0.36 pp |
| 2025 | 2025-04-25 | 9.49% | +2.26 pp |
| 2024 | 2024-04-26 | 7.23% | +0.00 pp |
| 2023 | 2023-04-28 | 7.22% | −2.47 pp |
| 2022 | 2022-04-29 | 9.69% | +2.63 pp |
| 2021 | 2021-04-30 | 7.06% | −2.44 pp |
| 2020 | 2020-04-24 | 9.50% | +0.31 pp |
| 2019 | 2019-04-26 | 9.19% | +3.04 pp |
| 2018 | 2018-04-27 | 6.15% | −1.73 pp |
| 2017 | 2017-04-28 | 7.88% | +1.16 pp |
| 2016 | 2016-04-29 | 6.72% | −0.64 pp |
| 2015 | 2015-04-24 | 7.36% | −8.72 pp |
| 2014 | 2014-04-25 | 16.08% | — |
Medtronic quarterly return on equity
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q1 2027 | 2026-07-31 | 2.95% | +0.78 pp |
| Q4 2026 | 2026-04-24 | 2.53% | +0.36 pp |
| Q3 2026 | 2026-01-31 | 2.33% | −0.31 pp |
| Q3 2026 | 2026-01-23 | 2.34% | −0.30 pp |
| Q2 2026 | 2025-10-24 | 2.85% | +0.21 pp |
| Q1 2026 | 2025-07-25 | 2.17% | +0.05 pp |
| Q4 2025 | 2025-04-25 | 2.17% | +0.89 pp |
| Q3 2025 | 2025-01-24 | 2.64% | +0.08 pp |
| Q2 2025 | 2024-10-25 | 2.63% | +0.86 pp |
| Q1 2025 | 2024-07-26 | 2.12% | +0.58 pp |
| Q4 2024 | 2024-04-26 | 1.28% | −1.01 pp |
| Q3 2024 | 2024-01-26 | 2.56% | +0.20 pp |
| Q2 2024 | 2023-10-27 | 1.77% | +0.95 pp |
| Q1 2024 | 2023-07-28 | 1.54% | −0.22 pp |
| Q4 2023 | 2023-04-28 | 2.29% | −0.53 pp |
| Q3 2023 | 2023-01-27 | 2.37% | −0.47 pp |
| Q2 2023 | 2022-10-28 | 0.82% | −1.72 pp |
| Q1 2023 | 2022-07-29 | 1.77% | +0.28 pp |
| Q4 2022 | 2022-04-29 | 2.83% | +0.16 pp |
| Q3 2022 | 2022-01-28 | 2.83% | +0.31 pp |
| Q2 2022 | 2021-10-29 | 2.53% | +1.56 pp |
| Q1 2022 | 2021-07-30 | 1.48% | +0.52 pp |
| Q4 2021 | 2021-04-30 | 2.66% | +1.40 pp |
| Q3 2021 | 2021-01-29 | 2.52% | −1.22 pp |
| Q2 2021 | 2020-10-30 | 0.97% | −1.73 pp |
| Q1 2021 | 2020-07-31 | 0.96% | −0.76 pp |
| Q4 2020 | 2020-04-24 | 1.26% | −1.09 pp |
| Q3 2020 | 2020-01-24 | 3.74% | +1.19 pp |
| Q2 2020 | 2019-10-25 | 2.70% | +0.47 pp |
| Q1 2020 | 2019-07-26 | 1.72% | −0.41 pp |
| Q4 2019 | 2019-04-26 | 2.35% | −0.55 pp |
| Q3 2019 | 2019-01-25 | 2.55% | +5.28 pp |
| Q2 2019 | 2018-10-26 | 2.23% | −1.72 pp |
| Q1 2019 | 2018-07-27 | 2.13% | +0.12 pp |
| Q4 2018 | 2018-04-27 | 2.89% | +0.56 pp |
| Q3 2018 | 2018-01-26 | −2.73% | −4.38 pp |
| Q2 2018 | 2017-10-27 | 3.95% | +1.74 pp |
| Q1 2018 | 2017-07-28 | 2.01% | +0.21 pp |
| Q4 2017 | 2017-04-28 | 2.34% | +0.19 pp |
| Q3 2017 | 2017-01-27 | 1.65% | −0.48 pp |
| Q2 2017 | 2016-10-28 | 2.21% | +1.22 pp |
| Q1 2017 | 2016-07-29 | 1.81% | +0.26 pp |
| Q4 2016 | 2016-04-29 | 2.15% | +2.15 pp |
| Q3 2016 | 2016-01-29 | 2.12% | — |
| Q2 2016 | 2015-10-30 | 0.99% | — |
| Q1 2016 | 2015-07-31 | 1.55% | — |
| Q4 2015 | 2015-04-24 | −0.00% | — |
Medtronic return on equity trends
Over the last five fiscal years, Medtronic's return on equity increased from 7.06% to 9.85%, a change of +2.79 percentage points. The latest reported quarter, Q1 2027, shows 2.95%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medtronic source filings ↗Community posts
Medtronic gains cardiac-software clearances across two ablation platforms
Medtronic ($MDT) obtained FDA clearance and a European CE mark for its latest Affera Prism-2 cardiac mapping software, alongside a CE mark for the PulseSelect ProxBox adapter and Proximity Indicator software. The Affera upgrade adds tools f ...
Medtronic’s GI Genius system shows gains in large clinical-practice study
Cosmo reported new results for GI Genius, the AI-assisted endoscopy system it develops and Medtronic ($MDT) commercializes. The cluster-randomized quality-improvement study covered more than 334,000 colonoscopies across 139 US Veterans Heal ...
Medtronic wins FDA clearance for LigaSure instrument on Hugo robot
Medtronic ($MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument for its Hugo robotic-assisted surgery system. The instrument brings the company’s vessel-sealing technology to the robotic platform and is designed to seal ...
Medtronic launches MiniMed share-exchange offer
Medtronic ($MDT) launched an exchange offer to split off at least 80.1% of MiniMed ($MMED), its former diabetes business. Investors can voluntarily exchange Medtronic shares for MiniMed stock at a 7% discount, subject to a cap of 4.5939 Min ...
Medtronic begins European clinical use of its Stealth AXiS surgical system
Medtronic ($MDT) announced the first European procedures using its Stealth AXiS surgical system, with more than 23 procedures performed across seven sites in Germany, the UK, Italy and Spain. The initial experience includes spinal surgery. ...
